Weaker API Sales Lead Chinese Companies To Focus on Pharmaceutical Formulations
This article was originally published in PharmAsia News
Executive Summary
Increased competition for active pharmaceutical ingredients (APIs) has led many Chinese companies to look to switch to making drug formulations via R&D and/or acquisition, according to a report.